What smart money is saying about AbbVie Inc
1 fund in our archive has pitched AbbVie Inc — most recently Baron Health Care Fund in September 2025.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Get an email when a fund writes about it
Position history
Between Q3 2025 and Q2 2026, 5 fund letters reported a position in AbbVie Inc — 2 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 5 | 0 | 2 | 0 |
| Q3 2025 | 0 | 0 | 0 | 1 |
Fund activity · 5 positions · 2 moves
- TrimmedDistillate CapitalJune 2026
“AbbVie, Inc. 2.0% 3.2%”
AbbVie Inc - June 2026
Listed in Harding Loevner Global Equity’s reported holdings.
AbbVie Inc - June 2026
Listed in Guinness Global Equity Income Fund’s reported holdings.
AbbVie Inc - June 2026
“Portfolio Highlights The ClearBridge Appreciation Strategy underperformed the benchmark S&P 500 Index in the second quarter of 2026. On an absolute basis, the Strategy had positive contributions from eight of 11 sectors. The IT sector was the main positive contributor, while energy was the main detractor. In relative terms, stock selection and sector allocation detracted. Stock selection in IT, industrials, communication services, financials and consumer discretionary, overweights to materials and energy and an IT underweight detracted the most. Conversely, stock selection in materials and a consumer discretionary underweight were beneficial. On an individual stock basis, the biggest relative contributors during the quarter were ASML, Palo Alto Networks, ASM International, an underweight to Microsoft and not owning Palantir. The biggest detractors were Netflix, underweights to Micron Technology and Advanced Micro Devices, and not owning Intel and Applied Materials. During the quarter, we initiated new positions in SpaceX in communication services, Micron Technology, Cisco Systems, Advanced Micro Devices and Texas Instruments in IT and Diamondback Energy in energy. We exited Roblox in communication services, Boston Scientific and AbbVie in health care and Solstice Advanced Materials in materials.”
AbbVie Inc - June 2026
“Top 10 holdings Weighting (%) Alphabet Inc. Class A 6.43 Apple Inc. 3.55 Micron Technology, Inc. 3.08 Microsoft Corporation 2.87 Taiwan Semiconductor Manufacturing Co., Ltd. Sponsored ADR 2.85 JPMorgan Chase & Co. 2.30 Cisco Systems, Inc. 2.15 AbbVie, Inc. 2.10”
AbbVie Inc
Also mentioned · 1
These funds discuss AbbVie Inc — as a competitor, benchmark or comparable — without disclosing a position in it.
- MentionedBaron Health Care FundJune 2026
“Favorable stock selection in biotechnology, mostly attributable to acquisition target Apogee Therapeutics, Inc. , was partly offset by higher exposure to this underperforming sub-industry. In June, Apogee announced an agreement to be acquired by AbbVie Inc. for $135.11 per share, representing a 49.5% premium over the prior day’s closing stock price.”
AbbVie Inc
Fund coverage · 1 thesis
- Baron Health Care FundSeptember 2025
AbbVie Inc. is a large biopharmaceutical company poised for sustained growth due to strong product offerings and no major patent expirations until the mid-2030s.
Read the full thesis
Read every full thesis on AbbVie Inc
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→